Abstract

Mutations in the human MECP2 gene cause Rett syndrome (RTT), a severe neurodevelopmental disorder that predominantly affects girls. Despite decades of work, the molecular function of MeCP2 is not fully understood. Here we report a systematic identification of MeCP2-interacting proteins in the mouse brain. In addition to transcription regulators, we found that MeCP2 physically interacts with several modulators of RNA splicing, including LEDGF and DHX9. These interactions are disrupted by RTT causing mutations, suggesting that they may play a role in RTT pathogenesis. Consistent with the idea, deep RNA sequencing revealed misregulation of hundreds of splicing events in the cortex of Mecp2 knockout mice. To reveal the functional consequence of altered RNA splicing due to the loss of MeCP2, we focused on the regulation of the splicing of the flip/flop exon of Gria2 and other AMPAR genes. We found a significant splicing shift in the flip/flop exon toward the flop inclusion, leading to a faster decay in the AMPAR gated current and altered synaptic transmission. In summary, our study identified direct physical interaction between MeCP2 and splicing factors, a novel MeCP2 target gene, and established functional connection between a specific RNA splicing change and synaptic phenotypes in RTT mice. These results not only help our understanding of the molecular function of MeCP2, but also reveal potential drug targets for future therapies.

Highlights

  • Rett syndrome (RTT) is a progressive neurodevelopmental disorder that predominantly affects females[1, 2]

  • We discovered that MeCP2 interacts with splicing factors to regulated the splicing of glutamate receptor genes, which mediate the vast majority of excitatory synaptic transmission in the brain; and linked the altered splicing of glutamate receptor genes to specific synaptic changes in a RTT mouse model

  • Gene ontology (GO) analysis showed that proteins identified by co-IP/MS were enriched with gene ontology (GO) terms of chromatin organization, chromatin modification and regulation of transcription

Read more

Summary

Introduction

Rett syndrome (RTT) is a progressive neurodevelopmental disorder that predominantly affects females[1, 2]. Previous research on the molecular function of MeCP2 has focused on the localization of MeCP2 in the nucleus and the proteins that physically interact with MeCP2. MeCP2 can bind to unmethylated DNA[7], methylated cytosine[5], and hydroxymethylated cytosine[8], and may preferentially modulate the expression of long genes[9]. Based on the known functions of identified MeCP2-interacting proteins, previous studies have suggested a role for MeCP2 in maintaining DNA methylation[10], regulating transcription[11,12,13,14,15,16], chromatin structure[17,18,19,20,21,22], and RNA processing[23,24,25]. Future effort to combine the insights from the two approaches described above may allow more detailed understanding of the regulation of each of these specific protein-protein interactions across the entire genome, as well as the relevance of each interaction to RTT disease pathogenesis

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call